Key facts
- This page summarizes Scott W. Morrison's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2026, 16:06.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Footnote F1
The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
Footnote F2
The Reporting Person is trustee of the Morrison-Minton Family 2004 Trust, and the Reporting Person and his spouse are the sole beneficiaries of the trust.
Footnote F3
Each RSU represents a contingent right to receive one share of the Company's common stock.
Footnote F4
RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.